



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

12th February 2025
IOLCP/CGC/2025

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Security Symbol: IOLCP

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai- 400 001
Security Code: 524164

Subject: Press Release: Financial Results for the quarter and nine months ended 31st December 2024.

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed a Press Release dated 12th February 2025 with respect to financial results for the quarter and nine months ended 31st December 2024.

Hope you will find the same in order.

Thanking You,

Yours faithfully,
for **IOL Chemicals and Pharmaceuticals Limited**

Abhay Raj Singh
Sr. Vice President & Company Secretary



IOL Chemicals And Pharmaceuticals Limited

For immediate release

IOL Chemicals and Pharmaceuticals reports Q3 & 9M FY25 Results

12th February 2025, Ludhiana:

IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for quarter and nine months year ended 31st December 2024.

Standalone Q3 & 9M FY25 Financial Highlights (₹ in Crore)

Particulars	Q3 FY25	Q2 FY25	% QoQ	Q3 FY24	% YoY	9M FY25	9M FY24	% YoY
Total Income	527.37	532.18	-0.90	528.77	-0.26	1569.31	1651.42	-4.97
EBITDA	50.94	47.99	6.15	52.86	-3.63	157.11	203.99	-22.98
EBITDA Margin (%)	9.66%	9.02%	64 bps	10.00%	-34 bps	10.01%	12.35%	-234 bps
PAT	20.55	19.15	7.31	23.23	-11.54	69.38	107.23	-35.30
PAT Margin (%)	3.90%	3.60%	30 bps	4.39%	-49 bps	4.42%	6.49%	-207 bps

Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “We are pleased to report our Q3FY25 Results as despite challenges such as pricing pressures, stagnant demand, and intense market competition, the company has successfully maintained stable and sustainable performance. This resilience reflects our strategic approach and adaptability in a dynamic business environment.

Confident of our resilient performance, the Board has declared an interim dividend of Rs. 4/- (40%) per share of face value of Rs 10 each for financial year 2024-25 and fixed a Record Date for 18th February 2025 for ascertaining the entitlement. Moving forward, we remain committed to our long-term vision by focusing on market diversification and expansion to unlock new growth opportunities. Additionally, we are implementing comprehensive cost optimization measures to enhance operational efficiency, improve profitability, and reinforce our competitive position. ”

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Established in 1986 and listed on the National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164), IOL Chemicals and Pharma is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP



IOL Chemicals And Pharmaceuticals Limited

has a wide presence across major therapeutic categories like pain management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.

The Company's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

The company is the World's largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with a 17 MW captive Co-Generation plant for self-reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including the UK, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.